Healthcare › Drug Manufacturers
Johnson & Johnson
- Ticker
- JNJ
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers
Price data arrives in a later stage, so no price is shown yet.
Latest news
ImportantJNJ
Explain this story: Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years?
This article compares the dividend prospects of Microsoft (MSFT) and Johnson & Johnson (JNJ) over a 10-year period. While Microsoft has a lower current yield but faster dividend growth, Johnson & Johnson offers a higher initial payout and, despite slower growth, is projected to pay more in cumulative dividends over the decade. The author concludes that for income-focused investors, J&J is the better choice for dividend income, although Microsoft might offer superior total returns through capital appreciation.
OtherTIKR.comSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
This article compares the dividend prospects of Microsoft (MSFT) and Johnson & Johnson (JNJ) over a 10-year period. While Microsoft has a lower current yield but faster dividend growth, Johnson & Johnson offers a higher initial payout and, despite slower growth, is projected to pay more in cumulative dividends over the decade. The author concludes that for income-focused investors, J&J is the better choice for dividend income, although Microsoft might offer superior total returns through capital appreciation.
This describes the words the journalist used. It is not a prediction, and not advice.
ImportantJNJ
Explain this story: BofA Securities Raises Price Target on Johnson & Johnson to $278 From $263, Keeps Neutral Rating
BofA Securities has increased its price target for Johnson & Johnson (JNJ) to $278 from $263, while maintaining a neutral rating on the stock. This adjustment reflects the analyst's updated valuation for the pharmaceutical and medical device giant. The article also briefly mentions JNJ's current stock performance and upcoming earnings release.
Otherwww.marketscreener.com
ImportantJNJ
Explain this story: Johnson & Johnson (JNJ) PT Raised to $278 at BofA Securities
BofA Securities analyst Jason M. Gerberry has raised the price target for Johnson & Johnson (NYSE: JNJ) to $278.00, an increase from the previous target of $263.00. This article, available exclusively to premium subscribers, reports on the analyst's updated rating for the pharmaceutical and medical device giant.
OtherStreetInsiderSector and industry: Healthcare
Company newsMDT
Explain this story: Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
OtherMedTech DiveHealthcare
Elsewhere
These links open other websites. We do not provide price data yet.